Ranbaxy launches Soliten for treatment of urology disorder

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy launches Soliten for treatment of urology disorder

Ranbaxy launches Soliten for treatment of urology disorder

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of its brand Soliten (Solifenacin), in the Indian market for the management of chronic urological disorder. The product is being introduced for the first time in India. Soliten will be sold in dosage forms of 5 mg and 10 mg tablets. 

Soliten is a new and safer formulation that will provide effective relief from chronic problems of Overactive Bladder (OAB) which lead to symptoms such as inability to hold urine coupled with urgency and increased frequency to pass urine. The product is documented to have lesser side effects and greater effectiveness. 

Commenting on the launch, Sanjeev I. Dani, Regional Director, India & Middle East, Ranbaxy, said, "An overactive bladder largely remains untreated due to prevailing low awareness amongst its sufferers. The introduction of Soliten will strengthen the options available to urologists in treating the symptoms of this highly uncomfortable and annoying medical condition. The Ranbaxy Urology franchise has become a leader in its category in a short span of 3 years since its launch and the introduction of Soliten should help to further consolidate this position." 

Speaking on the launch of Soliten, Dr Gopal Badlani, a leading Urologist from the Long Island Jewish Medical Centre, USA, said, " Solifenacin is a relatively new drug and has been present in the US for around 2 years. The drug has exhibited certain unique advantages over the current available therapy, which makes it different and an interesting new agent for the treatment of OAB with predominant urgency, a common ailment. It is being introduced in India soon after the international launch and will lead to significant improvement in the quality of life of patients suffering from the disease ." 

One out of every eleven individuals in the above 40 age group  is believed to suffer from an Overactive Bladder. The problem is equally common in males as well as females and more dominant among the urban population.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.  The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries.

Sourced From: Ranbaxy Laboratories Ltd